bluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET

Company Participants

Courtney O'Leary - IR
Andrew Obenshain - CEO
Tom Klima - Chief Commercial and Operating Officer
Chris Krawtschuk - CFO

Conference Call Participants

Jason Gerberry - Bank of America
Jack Allen - Baird
Gena Wang - Barclays
Eric Joseph - JPMorgan
Eric Schmidt - Cantor Fitzgerald
Lisa Walter - RBC Capital Markets
Brooke Schuster - William Blair

Operator

Thank you for standing by, and welcome to the bluebird bio First Quarter 2024 Results Call. [Operator Instructions] Finally, you are reminded that this conference is being recorded.

I would like to turn the call over to Courtney O'Leary from Investor Relations. Please go ahead.

Courtney O'Leary

Good morning, everyone, and thank you for joining our first quarter 2024 results call today. My name is Courtney O'Leary, Director of Investor Relations at bluebird bio. Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position, in addition to statements of the company's plans, expectations or intentions regarding regulatory progress, commercialization plans and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com. On today's call, Andrew Obenshain, bluebird bio's CEO, will provide opening remarks. Then Tom Klima, Chief Commercial and Operating Officer will discuss progress on the commercial launches of LYFGENIA, ZYNTEGLO and SKYSONA. And finally, Chris Krawtschuk, Chief Financial Officer will provide a financial update before opening the call up for Q&A. With that, I will turn it over to Andrew.

Andrew Obenshain

Thanks, Courtney, and thank you, everyone, for joining the call this morning as we provide an update on our first quarter 2024 results and recent highlights. I'm thrilled to be here today on the heels of our first LYFGENIA commercial sell collection, which we announced earlier this week, nearly a decade after we began clinical development for LYFGENIA for sickle cell disease, seeing a patient initiate commercial treatment for our gene therapy as a monumental milestone both for bluebird, for the researchers and the clinicians who worked tirelessly on this program, and also for the sickle cell community, who have been our partners every step of the way. Now with our first LYFGENIA patients start completed and with a strong established commercial foundation in place, bluebird is poised for accelerated growth throughout the rest of 2024, and we look forward to sharing more updates as momentum builds. I will now hand the call over to Tom to discuss the progress in our commercial launches in greater detail.